



00270

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

09/936,278

Filing Date

09/10/2001

First Named Inventor

George Foussias et al

Group Art Unit

1635

Examiner Name

Total Number of Pages in This Submission

9

Attorney Docket Number

MTS4USA

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment / Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☐ Response to Missing Parts/ Incomplete Application
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Other Enclosure(s) (please identify below):

Copies of (40) documents
are attached herewith**RECEIVED**

NOV 12 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual nameMary E. Bak, Esquire
Howson and Howson

Signature

Mary E. Bak

Date

Nov. 7, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270

PATENT TRADEMARK OFFICE

MTS4USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1635
George Foussias et al) Examiner:
Appln. No. 09/936,278)
Filed: September 10, 2001)
For: SIALIC ACID-BINDING IG-LIKE) November 7, 2002
LECTIN (SIGLEC) GENE; OB-BINDING)
PROTEIN LIKE (OB-BPL))

RECEIVED
TECH CENTER 1600/2900
02 NOV -7 PM 3:00

Commissioner for Patents
U.S. Patent and Trademark Office
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the references are enclosed herewith.

This Information Disclosure Statement is submitted more than three months from the filing date of this application, but prior to receipt of an Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants


By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9206
Telefacsimile: (215) 540-5818

RECEIVED

NOV 12 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → 

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	MTS4USA

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AL	WO	WO00/32221	A1	Genentech, Inc.	06/08/2000		
	AM	WO	WO00/12708	A1	Genentech, Inc.	03/09/2000		
	AN	EP	924,297	A1	SmithKline Beecham Corporation	06/23/1999		
	AO	EP	869,178	A1	SmithKline Beecham Corporation	10/07/1998		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002

TECH CENTER 1600/2900
PTO/SB/08B (08-00)Please type a plus sign (+) inside this box → 

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	MTS4USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AR	I. BERNSTEIN et al, "Differences in the Frequency of Normal and Clonal Precursors of Colony-Forming Cells in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia", Blood, 79(7):1811-1816 (April, 1992)	
	AS	L. BORGES et al, "A Family of Human Lymphoic and Myeloid Ig-Like Receptors, Some of Which Bind to MHC Class I Molecules", J. Immunol., 159:5192-5196 (1997)	
	AT	D. BURSHTYN et al, "A Novel Phosphotyrosine Motif with a Critical Amino Acid at Position -2 for the SH2 Domain-mediated Activation of the Tyrosine Phosphatase SHP-1", J. Biol. Chem., 272(20):13066-13072 (May, 1997)	
	AU	A. COFFEY et al, "Host Response to EBV Infection in X-Linked Lymphoproliferative Disease Results from Mutations in an SH2-Domain Encoding Gene", Nat. Genet., 20:129-135 (October, 1998)	
	AV	A. CORNISH et al, "Characterization of Siglec-5, a Novel Glycoprotein Expressed on Myeloid Cells Related to CD33", Blood, 92(6):2123-2132 (September, 1998)	
	AW	P. CROCKER et al, "Siglecs: a Family of Sialic-Acid Binding Lectins", Glycobiology, 8(2):v-vi (February, 1998) (Abstract only)	
	AX	P. CROCKER et al, "Sialoadhesin and Related Cellular Recognition Molecules of the Immunoglobulin Superfamily", Biochem. Soc. Trans., 24(1):150-156 (February, 1996) (Abstract only)	
	AY	P. CROCKER et al, "Sialoadhesin, a Macrophage Sialic Acid Binding Receptor for Haemopoietic Cells with 17 Immunoglobulin-Like Domains", EMBO J., 13(19):4490-4503 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	MTS4USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AZ	E. DIAMANDIS et al, "The New Human Kallikrein Gene Family: Implications in Carcinogenesis", Trends Endocrinol Metab., 11(2):54-60 (2000)			
	AAR	P. DINNDORF et al, "Expression of Normal Myeloid-Associated Antigens by Acute Leukemia Cells", Blood, 67(4):1048-1053 (April, 1986)			
	AAS	M. FALCO et al, "Identification and Molecular Cloning of p75/AIRM1, a Novel Member of the Sialoadhesin Family that Functions as an Inhibitory Receptor in Human Natural Killer Cells", J. Exp. Med., 190(6):793-801 (September, 1999)			
	AAT	J. GRIFFIN et al, "A Monoclonal Antibody Reactive with Normal and Leukemic Human Myeloid Progenitor Cells", Leuk. Res., 8(4):521-534 (1984)			
	AAU	J. HANSEN et al, "Prediction of O-Glycosylation of Mammalian Proteins: Specificity Patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase", Biochem. J., 308:801-813 (1995)			
	AAV	J. HANSEN et al, "NetOglyc: Prediction of Mucin Type O-Glycosylation Sites Based on Sequence Context and Surface Accessibility", Glycoconj. J., 15(2):115-130 (February, 1998) (Abstract only)			
	AAW	Y. IIDA, "Quantification Analysis of 5'-Splice Signal Sequences in mRNA Precursors. Mutations in 5'-Splice Signal Sequence of Human β -Globin Gene and β -Thalassemia", J. Theor. Biol., 145:523-533 (1990)			
	AAX	F. JEANMOUGIN et al, "Multiple Sequence Alignment with Clustal X", Trends Biochem. Sci., 23:403-405 (October, 1998)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

NOV 12 2002

TECH CENTER 1600/2900

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → ☒

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	MTS4USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AAY	S. KELM et al, "Functional Groups of Sialic Acids Involved in Binding to Siglecs (Sialoadhesins) Deduced from Interactions with Syhnhthetic Analogues", Eur. J. Biochem., 255(3):663-672 (August, 1998)	
	AAZ	S. KOSSMAN et al, "A Phase I Trial of Humanized Mnoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia", Clin. Cancer Res., 5:2748-2755 (October, 1999)	
	BR	E. LE DREAN et al, "Inhibition of Antigen-Induced T Cell Response and Antibody-Induced NK Cell Cytotoxicity by NKG2A: Association of NKG2A with SHP-1 and SHP-2 Protein-Tyrosine Phosphatases", Eur. J. Immunol., 28:264-276 (1998)	
	BS	C. LI et al, "Myelin Associated Glycoprotein Modulates Glia-Axon Contact In Vivo", J. Neurosci. Res., 51:210-217 (1998)	
	BT	A. MAY et al, "Crystal Structure of the N-Terminal Domain of Sialoadhesin in Complex with 3' Sialyllactose at 1.85 Å Resolution", Mol. Cell., 1:719-728 ((April, 1998) (Abstract only)	
	BU	G. NICOLL et al, "Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and Monocytes", J. Biol. Chem., 274(48):34089-34095 (November, 1999)	
	BV	H. NIELSEN et al, "A Neural Network Method for Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of their Cleavage Sites", Int. J. Neural. Syst., 8(5-6):581-599 (October-December, 1997) (Abstract only)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002

TECH. CENTER 1600/2900
PROCESS 28(0500)Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	MTS4USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BW	N. PATEL et al, "OB-BP1/Siglec-6, a Leptin- and Sialic Acid-Binding Protein of the Immunoglobulin Superfamily", J. Biol. Chem., 274(32):22729-22738 (August, 1999)		
	BX	L. PEDRAZA et al, "The Myelin-Associated Glycoproteins: Membrane Disposition, Evidence of a Novel Disulfide Linkage Between Immunoglobulin-Like Domains, and Posttranslational Palmitylation", J. Cell. Biol., 111(6):2651-2661 (December, 1990)		
	BY	N. RAZI et al, "Masking and Unmasking of the Sialic Acid-Binding Lectin Activity of CD22 (Siglec-2) on B Lymphocytes", Proc. Natl. Acad. Sci. USA, 95:7469-7474 (June, 1998)		
	BZ	J. SAYOS et al, "The X-Linked Lymphoproliferative-Disease Gene Product SAP Regulates Signals Induced Through the Co-Receptor SLAM", Nature, 395:462-469 (October, 1998)		
	BBR	E. SIEVERS et al, "Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate", Blood, 93(11):3678-3684 (June, 1999)		
	BBS	I. STAMENKOVIC et al, "The B-Cell Antigen CD22 Mediates Monocyte and Erythrocyte Adhesion", Nature, 345(6270):74-77 (May, 1990) (Abstract only)		
	BBT	T. ULYANOVA et al, "The Sialoadhesin CD33 is a Myeloid-Specific Inhibitory Receptor", Eur. J. Immunol., 29:3440-3449 (1999)		
	BBU	P. VAN DER MERWE et al, "Localization of the Putative Sialic Acid-Binding Site on the Immunoglobulin Superfamily Cell-Surface Molecule CD22", J. Biol. Chem., 271(16):9273-9280 (April, 1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002

Please type a plus sign (+) inside this box → ☒

TECH CENTER 1800/2900

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,278
				Filing Date	September 10, 2001
				First Named Inventor	George Foussias et al
				Group Art Unit	1635
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	MTS4USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BBV	E. VIVIER et al, "Immunoreceptor Tyrosine-Based Inhibition Motifs", Immunol. Today, 18(6):286-291 (June, 1997)	
	BBW	A. WILLIAMS et al, "The Immunoglobulin Superfamily - Domains for Cell Surface Recognition", Annu. Rev. Immunol., 6:381-405 (1988)	
	BBX	A. WILLIAMS et al, "Structural Diversity in Domains of the Immunoglobulin Superfamily", Cold Spring Harb. Symp. Quant. Biol., 54:637-647 (1989)	
	BBY	G. YOUSEF et al, "Identification of Novel Human Kallikrein-Like Genes on Chromosome 19q13.3-q13.4", Anticancer Res., 19:2843-2852 (July, 1999)	
	BBZ	G. YOUSEF et al, "Prostate/KLK-L1 is a New Member of the Human Kallikrein Gene Family, is Expressed in Prostate and Breast Tissues, and is Hormonally Regulated", Cancer Res., 59:4252-4256 (September, 1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.